2024-03-28T22:58:28Z
https://tsukuba.repo.nii.ac.jp/oai
oai:tsukuba.repo.nii.ac.jp:02001440
2022-04-27T10:53:36Z
2780:1789
3:62:5298:7829
Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside
Fujimura, Taku
藤澤, 康弘
フジサワ, ヤスヒロ
FUJISAWA, Yasuhiro
Kambayashi, Yumi
Aiba, Setsuya
open access
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
According to clinical trials, BRAF kinase inhibitors in combination with MEK kinase inhibitors are among the most promising chemotherapy regimens for the treatment of advanced BRAF-mutant melanoma, though the rate of BRAF mutation gene-bearing cutaneous melanoma is limited, especially in the Asian population. In addition, drug resistance sometimes abrogates the persistent efficacy of combined therapy with BRAF and MEK inhibitors. Therefore, recent pre-clinical study-based clinical trials have attempted to identify optimal drugs (e.g., immune checkpoint inhibitors or histone deacetylase (HDAC) inhibitors) that improve the anti-melanoma effects of BRAF and MEK inhibitors. In addition, the development of novel protocols to avoid resistance of BRAF inhibitors is another purpose of recent pre-clinical and early clinical trials. This review focuses on pre-clinical studies and early to phase III clinical trials to discuss the development of combined therapy based on BRAF inhibitors for BRAF-mutant advanced melanoma, as well as mechanisms of resistance to BRAF inhibitors.
MDPI
2019-09
eng
journal article
http://hdl.handle.net/2241/0002001440
https://tsukuba.repo.nii.ac.jp/records/2001440
31514399
https://doi.org/10.3390/cancers11091342
2072-6694
Cancers
11
9
1342
https://tsukuba.repo.nii.ac.jp/record/2001440/files/Cancers_11-9.pdf
application/pdf
548 KB
2021-09-28